DOCSLIB.ORG

Differential Gene Expression During Placentation in Pregnancies Conceived with Different Fertility Treatments Compared with Spontaneous Pregnancies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differential Gene Expression During Placentation in Pregnancies Conceived with Different Fertility Treatments Compared with Spontaneous Pregnancies Differential gene expression during placentation in pregnancies conceived with different fertility treatments compared with spontaneous pregnancies Bora Lee, Ph.D.,a Alex F. Koeppel, Ph.D.,b Erica T. Wang, M.D., M.A.S.,a,c Tania L. Gonzalez, Ph.D.,a Tianyanxin Sun, Ph.D.,a Lindsay Kroener, M.D.,c Yayu Lin, M.S.,a Nikhil V. Joshi, M.D.,a,c Tejal Ghadiali, B.S.,a Stephen D. Turner, Ph.D.,b Stephen S. Rich, Ph.D.,b Charles R. Farber, Ph.D.,b Jerome I. Rotter, M.D.,d Yii-Der Ida Chen, Ph.D.,d Mark O. Goodarzi, M.D., Ph.D.,e Seth Guller, Ph.D.,f Bryna Harwood, M.D.,g Tania B. Serna, M.D.,g John Williams III, M.D.,c,h and Margareta D. Pisarska, M.D.a,c a Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California; b Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia; c Department of Obstetrics and Gynecology, University of California, Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, California; d LABiomed/Harbor-UCLA Medical Center, Torrance, California; e Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; f Department of Obstetrics/Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut; g Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California; and h Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California Objective: To identify differences in the transcriptomic profiles during placentation from pregnancies conceived spontaneously vs. those with infertility using non-in vitro fertilization (IVF) fertility treatment (NIFT) or IVF. Design: Cohort study. Setting: Academic medical center. Patient(s): Women undergoing chorionic villus sampling at gestational age 11–13 weeks (n ¼ 141), with pregnancies that were conceived spontaneously (n ¼ 74), with NIFT (n ¼ 33), or with IVF (n ¼ 34), resulting in the delivery of viable offspring. Intervention(s): Collection of chorionic villus samples from women who conceived spontaneously, with NIFT, or with IVF for gene expression analysis using RNA sequencing. Main Outcome Measure(s): Baseline maternal, paternal, and fetal demographics, maternal medical conditions, pregnancy complica- tions, and outcomes. Differential gene expression of first-trimester placenta. Result(s): There were few differences in the transcriptome of first-trimester placenta from NIFT, IVF, and spontaneous pregnancies. There was one protein-coding differentially expressed gene (DEG) between the spontaneous and infertility groups, CACNA1I, one protein-coding DEG between the spontaneous and IVF groups, CACNA1I, and five protein-coding DEGs between the NIFT and IVF groups, SLC18A2, CCL21, FXYD2, PAEP, and DNER. Conclusion(s): This is the first and largest study looking at transcriptomic profiles of first-trimester placenta demonstrating similar transcriptomic profiles in pregnancies conceived using NIFT or IVF and spontaneous conceptions. Gene expression differences found to be highest in the NIFT group suggest that the underlying infertility, in addition to treatment-related factors, may Received May 30, 2018; revised November 3, 2018; accepted November 5, 2018; published online January 2, 2019. J.I.R. reports grants from the National Institutes of Health, during the conduct of the study. J.W. reports personal fees from Natera, Inc. outside the sub- mitted work. B.L. has nothing to disclose. A.F.K. has nothing to disclose. E.T.W. has nothing to disclose. T.L.G. has nothing to disclose. T.S. has nothing to disclose. L.K. has nothing to disclose. Y.L. has nothing to disclose. N.V.J. has nothing to disclose. T.G. has nothing to disclose. S.D.T. has nothing to disclose. S.S.R. has nothing to disclose. C.R.F. has nothing to disclose. Y.-D.I.C. has nothing to disclose. M.O.G. has nothing to disclose. S.G. has nothing to disclose. B.H. has nothing to disclose. T.B.S. has nothing to disclose. M.D.P. has nothing to disclose. Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number R01HD074368. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National In- stitutes of Health. Presented at the 65th Annual Meeting of the Society for Reproductive Investigation, San Diego, CA, March 6–10, 2018. Reprint requests: Margareta D. Pisarska, M.D., Cedars-Sinai Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocri- nology and Infertility, Los Angeles, California 90048 (E-mail: [email protected]). Fertility and Sterility® Vol. 111, No. 3, March 2019 0015-0282/$36.00 Copyright ©2018 American Society for Reproductive Medicine, Published by Elsevier Inc. https://doi.org/10.1016/j.fertnstert.2018.11.005 VOL. 111 NO. 3 / MARCH 2019 535 ORIGINAL ARTICLE: GENETICS contribute to the observed gene expression profiles. (Fertil SterilÒ 2019;111:535–46. Ó2018 by American Society for Reproductive Medicine.) El resumen está disponible en Español al final del artículo. Key Words: Non-IVF fertility treatment (NIFT), in vitro fertilization (IVF), placentation, RNA sequencing, transcriptome Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertility- and-sterility/posts/40658-26402 nfertility affects approximately 6.1 million people in the couples with infertility—that are in the late first trimester of United States, equivalent to 10% of the reproductive-age pop- pregnancy at the time of chorionic villus sampling (CVS) I ulation (1). The use of assisted reproductive technology (ART), and followed until delivery. Non-IVF fertility treatment was including in vitro fertilization (IVF), contributes to 1.5% of live defined as treatment using either medications for ovulation births in the United States, and other non-IVF fertility treatments induction or controlled ovarian stimulation and intrauterine (NIFTs) contribute to 4.6% (2, 3). Adverse pregnancy outcomes, insemination (IUI). IVF pregnancies included fresh or frozen including low birth weight and small for gestational age babies, embryo transfers using either cleavage-stage or blastocyst- pre-eclampsia, retained placenta, placental abruption, placenta stage embryos. Our SMAART Study cohort consisted of 409 previa, preterm labor and delivery, and birth defects, have been singleton pregnancies, of which 208 were spontaneous con- associated with ART compared with pregnancies conceived spon- ceptions and 201 pregnancies conceived with a history of taneously (2, 4–11).However,itisunclearwhethertheseadverse infertility. Of the infertility group, 90 were conceived with outcomes are the result of the ART procedures, such as IVF, or the NIFT and 111 were conceived with IVF. All pregnancies had underlying infertility, because pregnancies conceived by couples a normal karyotype and delivered (20). utilizing other types of fertility treatments, NIFT, are also at Transcriptomic profiling was performed on a subset of increased risk of adverse outcomes, including placental 141 subjects who had chorionic villi available from the first abruption, fetal loss, and gestational diabetes (12).Furthermore, trimester. The SMAART Transcriptome cohort consisted of pregnancies conceived in couples with infertility regardless of 74 spontaneous conceptions and 67 pregnancies conceived treatment are at increased risk of adverse outcomes, including with a history of infertility. Of the infertility group, 33 were placenta accreta (13), earlier gestational age at delivery, late conceived with NIFT and 34 were conceived with IVF. preterm birth, and greater neonatal intensive care unit – admissions (11, 14), as well as birth defects (15 17). Demographics Statistical Analysis Because many of these adverse outcomes are related to t placentation, a better understanding of placental function A -test and analysis of variance were used for the baseline in pregnancies conceived in couples with infertility, utilizing and pregnancy outcome demographics. fertility treatments, may uncover the underlying pathology leading to adverse outcomes. CVS Collection Previous studies examining the transcriptome of human Chorionic villus samples were collected at 11–13 weeks' placenta have been limited to term placentas with specific gestation at the Cedars-Sinai Prenatal Diagnostic Center, as placenta pathologies, predominantly pre-eclampsia (18). Yet previously described (21, 22). Leftover tissue after clinical it is during the first trimester of a pregnancy, during placenta- genetic testing was collected from consenting patients per tion, when trophoblast proliferation, differentiation, and inva- institutional review board–approved protocol and placed in sion, as well as angiogenesis and vasculogenesis, crucial for RNAlater RNA Stabilization Reagent (Qiagen) and stored at laying the groundwork for successful placental function, are À80C in the Cedars-Sinai Prenatal Biorepository until taking place; this is a necessary time point to study placental processing. development (19). It is also the closest time point to conception, either spontaneously or through fertility treatments, that can RNA Extraction for RNA-Sequencing be studied to minimize placental changes due to placental pa- thology and not the mode of conception. This is the first and Chorionic
Load more

Recommended publications
  • ATRX Induction by Mutant Huntingtin Via Cdx2 Modulates Heterochromatin Condensation and Pathology in Huntington’S Disease
    Cell Death and Differentiation (2012) 19, 1109–1116 & 2012 Macmillan Publishers Limited All rights reserved 1350-9047/12 www.nature.com/cdd ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington’s disease J Lee1,2, YK Hong3, GS Jeon4, YJ Hwang4, KY Kim4, KH Seong4, M-K Jung4, DJ Picketts5, NW Kowall1,2, KS Cho3 and H Ryu*,1,2,4 Aberrant chromatin remodeling is involved in the pathogenesis of Huntington’s disease (HD) but the mechanism is not known. Herein, we report that mutant huntingtin (mtHtt) induces the transcription of alpha thalassemia/mental retardation X linked (ATRX), an ATPase/helicase and SWI/SNF-like chromatin remodeling protein via Cdx-2 activation. ATRX expression was elevated in both a cell line model and transgenic model of HD, and Cdx-2 occupancy of the ATRX promoter was increased in HD. Induction of ATRX expanded the size of promyelocytic leukemia nuclear body (PML-NB) and increased trimethylation of H3K9 (H3K9me3) and condensation of pericentromeric heterochromatin, while knockdown of ATRX decreased PML-NB and H3K9me3 levels. Knockdown of ATRX/dXNP improved the hatch rate of fly embryos expressing mtHtt (Q127). ATRX/dXNP overexpression exacerbated eye degeneration of eye-specific mtHtt (Q127) expressing flies. Our findings suggest that transcriptional alteration of ATRX by mtHtt is involved in pericentromeric heterochromatin condensation and contributes to the pathogenesis of HD. Cell Death and Differentiation (2012) 19, 1109–1116; doi:10.1038/cdd.2011.196; published
    [Show full text]
  • Human CD64 / FCGR1A Protein (His Tag), Biotinylated
    Human CD64 / FCGR1A Protein (His Tag), Biotinylated Catalog Number: 10256-H08S-B General Information SDS-PAGE: Gene Name Synonym: CD64; Fc gamma RI Protein Construction: A DNA sequence encoding the human FCGR1A (NP_000557.1) (Met1- Pro288) was expressed with a polyhistidine tag at the C-terminus. The purified protein was biotinylated in vitro. Source: Human Expression Host: CHO Stable Cells QC Testing Purity: > 95 % as determined by SDS-PAGE. Bio Activity： Protein Description Measured by its binding ability in a functional ELISA.Immobilized High affinity immunoglobulin gamma Fc receptor I, also known as FCGR1 biotinylated Human CD64 Protein (Cat：10256-H08S-B)at 10 μg/mL can and CD64, is an integral membraneglycoprotein and a member of the bind human IgG1,The EC50 of human IgG1 is 6-14 ng/mL. immunoglobulin superfamily. CD64 is a high affinity receptor for the Fc region of IgG gamma and functions in both innate and adaptive immune Endotoxin: responses. Receptors that recognize the Fc portion of IgG function in the regulation of immune response and are divided into three classes < 1.0 EU per μg protein as determined by the LAL method. designated CD64, CD32, and CD16. CD64 is structurally composed of asignal peptidethat allows its transport to the surface of a cell, Stability: threeextracellularimmunoglobulin domainsof the C2-type that it uses to Samples are stable for up to twelve months from date of receipt at -70 ℃ bind antibody, a hydrophobictransmembrane domain, and a short cytoplasmic tail. CD64 isconstitutivelyfound on only macrophages and Predicted N terminal: Gln 16 monocytes, but treatment of polymorphonuclear leukocyteswith cytokines likeIFNγandG-CSFcan induce CD64 expression on these cells.
    [Show full text]
  • Systemic Restoration of UBA1 Ameliorates Disease in Spinal Muscular Atrophy
    Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy Rachael A. Powis, … , Mimoun Azzouz, Thomas H. Gillingwater JCI Insight. 2016;1(11):e87908. https://doi.org/10.1172/jci.insight.87908. Research Article Neuroscience Therapeutics The autosomal recessive neuromuscular disease spinal muscular atrophy (SMA) is caused by loss of survival motor neuron (SMN) protein. Molecular pathways that are disrupted downstream of SMN therefore represent potentially attractive therapeutic targets for SMA. Here, we demonstrate that therapeutic targeting of ubiquitin pathways disrupted as a consequence of SMN depletion, by increasing levels of one key ubiquitination enzyme (ubiquitin-like modifier activating enzyme 1 [UBA1]), represents a viable approach for treating SMA. Loss of UBA1 was a conserved response across mouse and zebrafish models of SMA as well as in patient induced pluripotent stem cell–derive motor neurons. Restoration of UBA1 was sufficient to rescue motor axon pathology and restore motor performance in SMA zebrafish. Adeno- associated virus serotype 9–UBA1 (AAV9-UBA1) gene therapy delivered systemic increases in UBA1 protein levels that were well tolerated over a prolonged period in healthy control mice. Systemic restoration of UBA1 in SMA mice ameliorated weight loss, increased survival and motor performance, and improved neuromuscular and organ pathology. AAV9-UBA1 therapy was also sufficient to reverse the widespread molecular perturbations in ubiquitin homeostasis that occur during SMA. We conclude that UBA1 represents a safe and effective therapeutic target for the treatment of both neuromuscular and systemic aspects of SMA. Find the latest version: https://jci.me/87908/pdf RESEARCH ARTICLE Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy Rachael A.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Figure S1. Representative Report Generated by the Ion Torrent System Server for Each of the KCC71 Panel Analysis and Pcafusion Analysis
    Figure S1. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. A Figure S1. Continued. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. B Figure S2. Comparative analysis of the variant frequency found by the KCC71 panel and calculated from publicly available cBioPortal datasets. For each of the 71 genes in the KCC71 panel, the frequency of variants was calculated as the variant number found in the examined cases. Datasets marked with different colors and sample numbers of prostate cancer are presented in the upper right. *Significantly high in the present study. Figure S3. Seven subnetworks extracted from each of seven public prostate cancer gene networks in TCNG (Table SVI). Blue dots represent genes that include initial seed genes (parent nodes), and parent‑child and child‑grandchild genes in the network. Graphical representation of node‑to‑node associations and subnetwork structures that differed among and were unique to each of the seven subnetworks. TCNG, The Cancer Network Galaxy. Figure S4. REVIGO tree map showing the predicted biological processes of prostate cancer in the Japanese. Each rectangle represents a biological function in terms of a Gene Ontology (GO) term, with the size adjusted to represent the P‑value of the GO term in the underlying GO term database.
    [Show full text]
  • FCGR1A Recombinant Protein
    FCGR1A Recombinant Protein CATALOG NUMBER: 96-305 The purity of rh CD64 / FCGR1A was determined by DTT-reduced (+) SDS- PAGE and staining overnight with Coomassie Blue. Specifications SPECIES: Human SOURCE SPECIES: HEK293 cells SEQUENCE: Gln 16 - Pro 288 FUSION TAG: His Tag TESTED APPLICATIONS: WB APPLICATIONS: This recombinant protein can be used for WB. For research use only. BIOLOGICAL ACTIVITY: Measured by its ability to bind human IgG1 in the SPR assay (Biacore 2000) with the KD < 5 nM. Measured by its binding ability in a functional ELISA. Immobilized Human IgG4 at 10ug/mL (100 µl/well),can bind Human Fc gamma RI, His Tag (Cat# FCA-H52H2) with a linear of 0.1-2 ng/mL. Properties PURITY: >90% as determined by SDS-PAGE. PREDICTED MOLECULAR 32.5 kDa WEIGHT: PHYSICAL STATE: Lyopholized BUFFER: PBS, pH7.4 STORAGE CONDITIONS: Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles. Additional Info ALTERNATE NAMES: FCGR1A, FCG1, FCGR1, IGFR1, CD64, CD64A, FCRI ACCESSION NO.: AAH32634 Background Receptors that recognize the Fc portion of IgG are divided into three groups designated Fc gamma RI, RII, and RIII, also known respectively as CD64, CD32, and CD16. Fc gamma RI binds IgG with high affinity and functions during early immune responses. Fc gamma RII and RIII are low affinity receptors that recognize IgG as aggregates surrounding multivalent antigens during late immune responses. High affinity immunoglobulin gamma Fc receptor I is also known as FCGR1A, FCG1, FCGR1, CD64 and IGFR1, is a type of integral membrane glycoprotein that binds monomeric IgG-type antibodies with high affinity, which belongs to the immunoglobulin superfamily or FCGR1 family.
    [Show full text]
  • Mitochondrial Heat Shock Protein 60: Evaluation of Its Role As a Neuroprotectant in Familial ALS and Its Mutation As a Cause of Hereditary Spastic Paraplegia
    Mitochondrial Heat Shock Protein 60: Evaluation of its role as a neuroprotectant in familial ALS and its mutation as a cause of hereditary spastic paraplegia By Laura A. Cooper Integrated Program in Neuroscience McGill University, Montreal June 2011 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of master’s in science © Laura A. Cooper, 2011 TABLE OF CONTENTS ABSTRACT…………………………………………………………………………….vi RÉSUMÉ……………………………………………………………………………….viii ACKNOWLEDGMENTS……………………………………………………………..xi LIST OF FIGURES……………………………………………………………………xiii ABBREVIATIONS………………………………………………………………….....xv INTRODUCTION……………………………………………………………………..xx CHAPTER 1 – Literature Review 1.1 Amyotrophic Lateral Sclerosis 1.1.1 Clinical Overview..................................................................................................1 1.1.2 Sporadic ALS…………………………………………………………………….2 1.1.3 Familial ALS……………………………………………………………………..4 1.1.4 Cu/Zn Superoxide Dismutase Mutation and fALS……………………………….4 1.1.5 Protein Aggregation in SOD1-Related fALS…………………………………….5 1.1.6 Mitochondrial Abnormalities in Mouse Models of SOD1-Related fALS………..7 1.1.7 Relationship Between Mutant SOD1 and Mitochondrial Abnormalities………..8 1.2 Heat Shock Proteins 1.2.1 Normal Function in the Central Nervous System and Relevance to ALS……….9 1.2.2 Heat Shock Proteins as a Therapeutic Target in ALS………………………….10 1.3 Mitochondrial Heat Shock Protein Hsp60 1.3.1 Structure and Function………………………………………………………....12 ii 1.3.2 Mitochondrial Hsp60 in Neuroprotection…………………………………….
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Folate Receptor Β Regulates Integrin Cd11b/CD18 Adhesion of a Macrophage Subset to Collagen
    Folate Receptor β Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen This information is current as Christian Machacek, Verena Supper, Vladimir Leksa, Goran of September 24, 2021. Mitulovic, Andreas Spittler, Karel Drbal, Miloslav Suchanek, Anna Ohradanova-Repic and Hannes Stockinger J Immunol 2016; 197:2229-2238; Prepublished online 17 August 2016; doi: 10.4049/jimmunol.1501878 Downloaded from http://www.jimmunol.org/content/197/6/2229 Supplementary http://www.jimmunol.org/content/suppl/2016/08/17/jimmunol.150187 Material 8.DCSupplemental http://www.jimmunol.org/ References This article cites 49 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/197/6/2229.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Folate Receptor b Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen Christian Machacek,* Verena Supper,* Vladimir Leksa,*,† Goran Mitulovic,‡ Andreas Spittler,x Karel Drbal,{,1 Miloslav Suchanek,{ Anna Ohradanova-Repic,* and Hannes Stockinger* Folate, also known as vitamin B9, is necessary for essential cellular functions such as DNA synthesis, repair, and methylation.
    [Show full text]
  • ASCL2 Expression Contributes to Gastric Tumor Migration and Invasion by Downregulating Mir223 and Inducing EMT
    MOLECULAR MEDICINE REPORTS 18: 3751-3759, 2018 ASCL2 expression contributes to gastric tumor migration and invasion by downregulating miR223 and inducing EMT QINGSONG ZUO*, JIE WANG*, CHAO CHEN, YONG ZHANG, DIAN-XU FENG, RONGHUA ZHAO and TENG CHEN Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China Received May 15, 2017; Accepted November 23, 2017 DOI: 10.3892/mmr.2018.9363 Abstract. Achaete-scute homolog 2 (ASCL2), a basic results of the present study demonstrated that ASCL2 was able helix-loop-helix transcription factor, serves an essential role in to downregulate the expression level of miR223, contribute to the maintenance of adult intestinal stem cells and the growth EMT and promote gastric tumor metastasis, which indicated of gastric cancer (GC). However, the function of ASCL2 in that ASCL2 may serve as a therapeutic target in the treatment the metastasis of GC is poorly understood. The present study of GC. aimed to evaluate the effect of ASCL2 expression on gastric tumor metastasis. ASCL2 protein expression was detected in Introduction 32 cases of gastric metastasis and its relevant primary tumors using western blotting and immunohistochemistry. The Gastric cancer (GC) is the second most common cause of data suggested that the expression of ASCL2 was highest in cancer-associated mortality in the world, and the incidence metastatic tumors, among adjacent normal tissues, primary GC is highest in East Asia, Eastern Europe and parts of Latin gastric tumors and gastric metastatic tumors. Furthermore, America (1,2). However, the precise mechanisms underlying ASCL2-overexpressing GC cell lines MKN1-ASCL2 and gastric carcinogenesis are not yet completely understood (3).
    [Show full text]
  • Supplementary Table S1. Correlation Between the Mutant P53-Interacting Partners and PTTG3P, PTTG1 and PTTG2, Based on Data from Starbase V3.0 Database
    Supplementary Table S1. Correlation between the mutant p53-interacting partners and PTTG3P, PTTG1 and PTTG2, based on data from StarBase v3.0 database. PTTG3P PTTG1 PTTG2 Gene ID Coefficient-R p-value Coefficient-R p-value Coefficient-R p-value NF-YA ENSG00000001167 −0.077 8.59e-2 −0.210 2.09e-6 −0.122 6.23e-3 NF-YB ENSG00000120837 0.176 7.12e-5 0.227 2.82e-7 0.094 3.59e-2 NF-YC ENSG00000066136 0.124 5.45e-3 0.124 5.40e-3 0.051 2.51e-1 Sp1 ENSG00000185591 −0.014 7.50e-1 −0.201 5.82e-6 −0.072 1.07e-1 Ets-1 ENSG00000134954 −0.096 3.14e-2 −0.257 4.83e-9 0.034 4.46e-1 VDR ENSG00000111424 −0.091 4.10e-2 −0.216 1.03e-6 0.014 7.48e-1 SREBP-2 ENSG00000198911 −0.064 1.53e-1 −0.147 9.27e-4 −0.073 1.01e-1 TopBP1 ENSG00000163781 0.067 1.36e-1 0.051 2.57e-1 −0.020 6.57e-1 Pin1 ENSG00000127445 0.250 1.40e-8 0.571 9.56e-45 0.187 2.52e-5 MRE11 ENSG00000020922 0.063 1.56e-1 −0.007 8.81e-1 −0.024 5.93e-1 PML ENSG00000140464 0.072 1.05e-1 0.217 9.36e-7 0.166 1.85e-4 p63 ENSG00000073282 −0.120 7.04e-3 −0.283 1.08e-10 −0.198 7.71e-6 p73 ENSG00000078900 0.104 2.03e-2 0.258 4.67e-9 0.097 3.02e-2 Supplementary Table S2.
    [Show full text]